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Primary vesicoureteral reﬂux (VUR), traditionally considered a problem of childhood, can also be detected during adulthood.
However, while the concept regarding the therapeutic management of VUR in children has undergone revolutionary changes,
moving from surgical to conservative approach, the optimal therapeutic approach in adult reﬂux is poorly addressed and is still
unknown. Herein, we review clinical and therapeutic approaches of VUR in pediatric population as published throughout the
years. With the introduction of Deﬂux injection as a minimally invasive procedure, we identify a beginning of a new trend that
further extends the indications for endoscopic injections, including its introduction to adult patients as well.
Copyright © 2008 D. E. Zilberman and Y. Mor. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Primary vesicoureteral reﬂux (VUR), traditionally consid-
ered a problem of childhood, can also be detected during
adulthood [1]. However, while the concept regarding the
therapeutic management of VUR in children has undergone
revolutionary changes, moving from surgical to conservative
approach, based upon solid prospective data, the optimal
therapeutic approach in adult reﬂux is poorly addressed in
the literature and is still unknown. The current therapeutic
strategy for management of reﬂux has drawn its inspiration
from three important large prospective studies dealing with
the management of VUR [2–4]. The most comprehensive
was the International Reﬂux Study (IRS), where 452 patients
in Europe and USA were randomly allocated to medical
and surgical arms. In 5 years follow-up, the same incidence
of urinary tract infection (UTI) was seen in both arms
(38%), though surgery was more eﬀective in preventing
pyelonephritis (PN) (21% versus 10%). However, in 10 years
follow-up, clinical ﬁndings did not support the surgical
attitude as there was no signiﬁcant diﬀerence in renal growth
comparing both arms, and there was no support to the
view that the outcome of renal function is improved by
surgical correction of VUR in children with bilateral disease.
These studies had led to the publication of the clinical
guidelines for the management of VUR in children, both
by the American Urological Association (AUA) [5] and the
European Association of Urology (EAU) [6].
In general, conservative attitude is currently the main-
stay, and surgical intervention takes its place in the more
severe conditions. While those observations are extremly
importantinchildren,theyareirrelevantforadultsasfactors
such as the natural history of the disease, the associated
risks such as infections or scars are completely diﬀerent.
Unfortunately, with regard to VUR in adults, review of the
literaturerevealsonlyfewretrospectivestudies,someofthem
biased with conﬂicting results.
2. PREVALENCE OF VUR IN ADULTS
In the general pediatric population, the prevalence of VUR
is around 1-2% with higher rates in siblings (30%) and in
children with acute PN (25–40%) [5].
As the rates of disappearance of VUR in children are as
highas71%andcanoccuratanyage,ininfancyoratpuberty
[7], the actual prevalence in adults is still unclear. Baker
and coworkers [8] found an incidence of 26.4% of VUR in2 Advances in Urology
children but only 5.2% in adults, each group suspected of
“having infravesical obstruction”.
Similarly, Choi et al. [9] studied 86 adult women
suﬀeringfromuncomplicatedPNwithvoidingcystourethro-
gram (VCUG) performed on the 3rd and the 7th days of
antibiotic treatment, and only in 2 cases (2.3%), VUR was
demonstrated.
Pinthus et al. [10] explored the same situation in
47 women who presented with acute PN. Early indirect
cystography revealed VUR in 28%, while VCUG performed
later found VUR in only 3 patients (9%). In accordance,
while the resolution rates of reﬂux in children are rather
predicted, it seems that the possibility of resolution even past
puberty still exists, yet the chance for resolution is probably
much less than in infants [11].
3. PRESENTATION
The most common initial symptoms and ﬁndings that
can lead to the diagnosis of VUR are UTI, asymptomatic
bacteriuria, proteinuria, renal failure, and hypertension [12].
K¨ ohler et al. followed after 115 adult patients and found
UTIs in 87%, hypertension in 34%, renal calculi in 18%,
and back pain in 42% [12]. Vice versa, reﬂux nephropathy
may be clinically latent as the prevalence of reﬂux in patients
with incidentally diagnosed adult hypertension exceeds to
19%, without any apparent renal parenchymal or renovas-
cular involvement [13]. However, the correlation between
presence of VUR and various clinical presentations cannot
be made that easily as diﬀerent, and somehow confounding
observations were published in other studies and in some
patients the reﬂux may be even completely asymptomatic
[11].
4. THE CURRENT APPROACH FOR MANAGEMENT
OF ADULT VUR
So far, although no evidence-based recommendations are
availableintheliterature,thelastAUAupdate(1998)[11]for
the treatmentof VUR in adolescents and adults recommends
the following.
(i) No medical management is needed in VUR grade 1-2
and no history of UTI.
(ii) Medical management with lifelong antibacterial pro-
phylaxis should be considered in the cases of low-
grade VUR, shortened life expectancy, and poor
surgical risk.
(iii) SurgeryisindicatedinVURgrade3orhigher,history
of recurrent PN, and evidence of nephron loss.
When conservative treatment is the mainstay, progressive
renal damage and caliceal scarring should be expected [14].
Reimplantation, when performed, does not improve hyper-
tension or renal failure, but it rather stops the anticipated
progressive deterioration [10, 15].
Similar conclusions were coming up from K¨ ohler and
Guthman’s studies [16, 17]. In the ﬁrst study [16], surgical
treatment (e.g., ureteral reimplantation) did not alter the
frequency of lower UTI, though it signiﬁcantly decreased
the frequency of PN. Yet, the surgical option according to
the author should be considered only when conservative
treatment failed and not with the aim of arresting renal
functional deterioration. However, the second study [17]
had expanded the indications for surgical treatment also
for asymptomatic women in childbearing age “in whom
pyelonephritis of pregnancy would pose a major risk to
the fetus and mother”, without supporting evidences. Ever
since, most clinicians recommend that surgical correction of
VUR should be accomplished before pregnancy in women
at childbearing age or even earlier in girls with reﬂux that
persists beyond puberty.
This recommendation is based upon the fact that history
of VUR is known to increase morbidity during pregnancy
including the risk of preeclampsia, obstetric interventions,
and fetal loss. Women with hypertension and an element
of renal failure are particularly at risk, though surgical cor-
rection does not prevent complications but rather decreases
their frequency [18]. It should be also remembered that
reimplantation in adults is more diﬃcult with lower success
rates compared to infants. This can be attributed to diﬃcult
bladder exposition, increased vascularity around the ureter
and in the retrovesical space, and increased body mass [11].
Altogether, VUR in adults is still a very controversial
subject, and throughout the years, the pendulum had moved
from surgical to a more conservative treatment and again to
surgical treatment in certain and severe cases.
5. ENDOSCOPIC CORRECTION OF VUR
During the last seven years, we are witnessing an increasing
number of studies published in the English literature,
discussing the safety and eﬃcacy of endoscopic injection
of bulking materials for the correction of ureteric reﬂux.
The need for alternative treatment aroused as a result
of the signiﬁcant disadvantages of both reimplantation
and antibiotic prophylaxis. Reimplantation in the pediatric
population carries signiﬁcant cost, morbidity, and inpatient
hospital stay, while antibiotic prophylaxis requires annual
imaging which is expensive, invasive, and often requires
sedation [19].
The ﬁrst report on endoscopic injection of polytetraﬂuo-
roethylene (Teﬂon) in pigs came from Puri and O’Donnell
in 1984 [20]. Later on, long-term results were published
covering 8332 children and 12251 reﬂuxing ureters [21],
and the ﬁnal conclusion was that “polytetraﬂuoroethylene
injection is a simple, safe and eﬀective outpatient procedure
for treating all grades of vesicoureteral reﬂux.” Chertin and
Puri [22] supported their own conclusion by reporting
long-term (e.g., six years) follow-up among 258 patients
with primary VUR who were treated by polytetraﬂuo-
roethylene injection. They reported overall success rates of
77% following one injection, 13.5% success rate following
two injections, 2.6% following three injections, and 0.5%
following four injections. Yet, the initial enthusiasm from
PTFE has disappeared following the observation that small
particlescanbeinjecteddirectlyintocapillariesandembolize
to distant organs, causing the FDA to withdraw PTFED. E. Zilberman and Y. Mor 3
from the United States market [23]. Remaining with the
impressive results of the endoscopic injection for treating
vesicoureteric reﬂux, alternative materials took the PTFE
place in order to keep its momentum of success, while
keeping complication rates as low as possible. At present, the
most popular injectable material is dextranomer/hyaluronic
acid (Dx/HA) copolymer (Deﬂux) which is FDA approved.
This is an organic substance comprising 80–250µmm i c r o -
spheres which are nonallergic, nonimmunogenic, and have
no potential for malignant transformation [24, 25]. The
large size of the microspheres prevents them from migrating
outside the urinary bladder and they do not tend to form
granulomas or induce calciﬁcations [24].
Injection procedure consists of injecting the bulking
material through direct inspection and under general anes-
thesia. Approximately, 1mL of Deﬂux is submucosally
injected through a special needle, which is inserted 2-3mm
below the aﬀected ureteral oriﬁce at the 6 o’clock position
[25, 26]. The needle is slowly withdrawn as a “volcanic
bulge” starts to create [25]. Overall procedure length does
not exceed 30 minutes [26, 27], and the patient is discharged
home the same day [19, 23, 27, 28] or the following day [24].
Overall complication rate is very low, and the procedure
is considered very safe and eﬀective. UTI, ﬂank pain, postop-
erative ureteral obstruction, retrograde tracking of Deﬂux,
intravesical extravasation of Deﬂux, and new contralateral
VUR were reported in only few percents (0.6–4.5%) [23, 28,
29].
Success rates, on the other hand, are high and reported
in various series with regard to the number of injections
required to cure VUR and to the original reﬂux grade.
Following a single injection, the reported success rates
in pediatric population vary between 72–86%, follow-
ing two injections—between 12-13% and following three
injections—between1-2%[23,25,27,28].Overall,curerates
reached82–100%forgrade1reﬂux,82–88%forgrade2,73–
87% for grade 3, 64–73% for grade 4, and 50% for grade 5
[19,23,28].Kirschetal.[23]describethelowestsuccessrates
(60%) in the ﬁrst twenty cases, meaning that a reasonable
learning curve exists for this certain procedure.
6. THE EVOLVEMENT OF THE THERAPEUTIC
APPROACH IN ADULTS
All the advantages mentioned with regard to endoscopic
treatment for VUR in children can deﬁnitely change the
concept regarding the treatment of VUR in adults. Argu-
ments such as high success rates, very short hospital stay,
absence of signiﬁcant postoperative complications, safety of
injectable materials, and low cost compared to the cost of
long-termantibioticprophylactictreatmentwhichhavebeen
raised in discussions regarding children [30–32], are also
valid concerning adults. Understandably, this can widen the
circle of patients treated with bulking agents to include also
adults. However, in oppose to increasing reports regarding
using this technique in the pediatric age group, the reported
experience in adults with Deﬂux is very limited [19, 29, 33].
Those reports usually describe the outcome of injection of
various substances in series composed of mixed populations,
including children and adults. Although there is usually no
speciﬁc reference to the adult subgroup, it is obvious that
there has been some experience with injection of cross-
linked bovine collagen [34]o rS T I N G[ 35, 36] in adults,
with cure rates as high as 86% following the injection of
polymethylsiloxan in adult women or 70% following the ﬁrst
injection of Teﬂon in adults [36].
Nowadays, in the “Deﬂux era”, review of the literature as
well as presentations in urological conferences can identify
the beginning of a new trend that further extends the indica-
tions for endoscopic injections, including its introduction to
adultpatientsaswell.Somecurrentpediatricreports[19,29]
include in their series some adult patients as old as 22 years.
Unfortunately, they do not specify this unique population in
terms of number of individuals, sex, indications for Deﬂux
injection, age at injection, follow-up length, complications,
and success rates. However, we can assume that both
groups were stunned by their impressive success rates, and
taking into consideration that endoscopic treatment for
VUR is “self and eﬃcacious with low-complication rate”
[19], they decided to oﬀer it to certain individuals that
traditionally were excluded from any deﬁnitive treatment.
Enthusiasm from the introduction of Deﬂux injection for
adult population was also expressed by Kirsch [37]w h o
achieved success rates of 90 and 95% after one or two
treatmentsin22patientsranginginagebetween13–71years.
In summary, the eﬄux of data regarding the safety
and the promising results of Deﬂux endoscopic correction
of VUR in children will certainly change the management
of VUR in adults which unfortunately has been poorly
addressed and controversial till recently. In similar with the
shifting therapeutic policy of adult ureteropelvic junction
obstruction following the arrival of the endourological era
[38], one can likewise anticipate that “it would be unethical
to refrain from treating” [30] adult patients diagnosed with
VUR. Furthermore, as the procedure is safe, less invasive,
highly successful, and can be repeated, we foresee that a
more active strategy, namely, early endoscopic correction,
will become the new gold standard of treatment of adult
VUR, and we hope that this shift of policy will be clearly
reﬂected in the coming updated clinical urological guidelines
for management of VUR.
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